Vaccine
CoviVac
Developer
Chumakov Federal Science Center for Research and Development of Immunobiological Medications
Producer
Chumakov Federal Science Center for Research and Development of Immunobiological Medications, Institut Poliomelita Township, Moskovskiy Settlement, Moscow, Russia
Status
Registration certificate LP-006800 from February 19, 2021
On September 25, 2020, the Russian Ministry of Health approved clinical trials of the vaccine. The first phase of research examined the vaccine’s safety with an initial group of 200 vaccinations. No adverse effects were observed in these volunteers after vaccination. The second phase, during which the Center had to prove the effectiveness of the final vaccine, began in December 2020 in St. Petersburg, Novosibirsk and Kirov, involving another 200 volunteers. The vaccine was officially registered on February 20, 2021. The vaccine first entered public circulation on March 28. As of April 6, 70,000 doses had been distributed. Planned production will reach 1 million doses per month.
On June 2, 2021, permission was granted to begin the third phase of clinical trials, involving more than 30,000 volunteers
According to the Chumakov Center, a total of 1.5 million doses have been distributed as of September 23, 2021, with plans to release another 2.5 million doses by the end of the year. The third phase of trials will take place in Moscow and St. Petersburg. In addition, the Chumakov Center has modernized its production facilities to increase output by 200-250%.
Key information
What’s in the vaccine?
CoviVac is a classical whole-virion vaccine with an inactive virus. It is made from a “dead” (inactive) SARS-CoV-2 coronavirus, with an adjuvant of aluminum hydroxide.
